More women, more conversations
There are now around 64 million American women over 50, and most of them will spend decades of their lives after menopause. That demographic reality, combined with a wave of social media discussion, celebrity openness, podcasts, and better access to telehealth, has brought menopause back into the spotlight in a big way. A 2023 New York Times investigation also struck a nerve by documenting how many women felt dismissed or undertreated by their doctors in the years following a major 1990s study called the Women’s Health Initiative (WHI). All of this has created real momentum for updated, more nuanced guidance.
Rethinking the old fear around hormone therapy
For years, the WHI cast a long shadow over hormone therapy. But a landmark 2024 review published in JAMA, written by the WHI investigators themselves, made something clear: the risks identified in that study should not automatically apply to women in their 50s who are dealing with bothersome hot flashes or night sweats. Symptomatic women in this age group should be offered hormone therapy, and the old blanket caution simply doesn’t hold up for them.
How hormones are delivered matters more than we used to think
One of the more practice-changing shifts is a stronger preference for transdermal estrogen, patches, gels, or sprays applied to the skin, over oral pills. The reason comes down to how the body processes each form. Oral estrogen passes through the liver first, which appears to slightly raise the risk of blood clots (VTE). Transdermal estrogen bypasses that process, and the accumulated evidence suggests it doesn’t carry the same clotting risk.
There’s also been a meaningful shift in which progestogen is paired with estrogen for women who still have a uterus. Micronized progesterone, a form that closely resembles the body’s own progesterone, is now favored over an older synthetic version called medroxyprogesterone acetate (MPA). The evidence suggests it’s gentler on breast tissue, has a better metabolic profile, and carries less thrombotic risk.
Another option gaining more traction is using the 52mg levonorgestrel IUD (the highest-dose Mirena) to protect the uterine lining in women taking estrogen. It’s particularly useful when managing irregular bleeding is a concern, and data support its use for up to five years in this role.
A big regulatory change: the black box warning is gone
In November 2025, the FDA removed the black box warning that had long appeared on hormone therapy labeling. This is significant, especially for vaginal estrogen, which treats local symptoms like dryness and discomfort but has almost no systemic absorption. The original warning was based on WHI-era data that didn’t distinguish between different formulations, different ages of initiation, or local versus systemic therapy. Its removal reflects a more accurate picture of the risk landscape.
New non-hormonal options that actually work
For women who can’t or prefer not to use hormones, there are now targeted non-hormonal medications that go beyond older options like antidepressants. These drugs work on a specific brain pathway — neurokinin receptors — that plays a direct role in triggering hot flashes.
Fezolinetant (an NK3 receptor blocker) has shown roughly a 60% reduction in hot flash frequency in clinical trials. It does require periodic liver enzyme monitoring. A newer option, elinzanetant (which targets both NK1 and NK3 receptors), was FDA-approved in late 2025 and offers similar benefits with less frequent monitoring, though it’s worth noting it may cause some daytime drowsiness in certain patients.
Managing perimenopause is a different challenge
Perimenopause, the transition years before periods stop entirely, requires a different way of thinking. The problem during this phase isn’t just low estrogen; it’s wildly fluctuating estrogen. That hormonal rollercoaster, rather than a simple deficiency, is often what drives symptoms. Simply adding standard hormone therapy on top of that can lead to unpredictable bleeding and potentially push estrogen to higher-than-intended levels.
The updated approach leans toward suppression strategies — using continuous birth control pills or an IUD paired with estrogen — to first stabilize the hormonal environment, rather than supplementing an already erratic system. It’s a subtler distinction, but it makes a real difference in day-to-day symptom management and bleeding control
